Lucy Xiaolu Wang

Lucy Xiaolu Wang, Ph.D.

Affiliated Research Fellow

Innovation and Entrepreneurship Research
Assistant Professor, University of Massachusetts Amherst



Personal Website:

https://www.lucyxiaoluwang.com

Areas of Interest:

Economics of Innovation and Digitization, Health Care Economics, Industrial Organization, Public Finance, Law and Economics  

Academic Résumé

Since 4/2022
Faculty Affiliate, Public Interest Technology Initiative (PIT@UMass)
University of Massachusetts Amherst, Amherst, MA, USA

Since 9/2021
Affiliated Research Fellow
Max Planck Institute for Innovation and Competition

Since 9/2021
Assistant Professor (tenure track), Department of Resource Economics
Faculty Associate, Computational Social Science Institute
University of Massachusetts Amherst, Amherst, MA, USA

8/2020 - 8/2021
Senior Research Fellow at the Max Planck Institute for Innovation and Competition (Innovation and Entrepreneurship Research)

8/2014 – 5/2020
Ph.D. in Economics, Cornell University, Ithaca, New York
Dissertation Title: “Essays on Innovation and Digitization in Health Care Markets

8/2012 – 5/2014
M.A. in Economics, Duke University, Durham, North Carolina

9/2008 – 7/2012
B.A. in Economics (Specialty: Insurance), Central University of Finance and Economics, Beijing

Honors, Scholarships, Academic Prizes

2019 – 2020
Principal Investigator, Cornell SC Johnson College of Business “Innovation, Entrepreneurship, and Technology” (IET) Theme Inaugural Travel Grant ($2,000) (faculty co-PI: Chris Forman), Cornell University 

2016 – 2020
Conference Travel Grants (Graduate School; Economics Department; Policy Analysis & Management), Cornell University
Institute for Health Economics, Health Behaviors, and Disparities Student Grants (x5), Cornell University

2019
Best Paper Award, Wharton Innovation Doctoral Symposium, University of Pennsylvania
Young Scholar Best Paper Award (in economics/management), European Policy for Intellectual Property (EPIP), ETH Zürich
Best Paper Proceedings, Outstanding Student Paper Award Winner (William H. Newman Award Divisional Nominee), Student Travel Scholarship Award, and Finalist for Best Theory to Practice Paper, Healthcare Management Division, Academy of Management
Flora Rose & Flemmie Kittrell Summer Fellowship, Policy Analysis and Management, Cornell University
Graduate School Research Travel Grant ($2,000), Cornell University

2018 – 2019
Ernest Liu '64, Ta-Chung and Ya-Chao Liu Memorial Fellowship, Deptartment of Economics, Cornell University
Humane Studies Fellowship Grant ($5,000), Institute for Humane Studies at George Mason University

2018
Young Researcher Best Paper Award, The 9th Conference on Health IT & Analytics, Washington D.C.
CU-CIRTL Scholar Certificate Award, Center for the Integration of Research, Teaching & Learning, Cornell University

2017 – 2018
Selected Fellow Mentor, Graduate Teaching Assistant Fellowship ($1,000), Center for Teaching Innovation, Cornell University
Research Travel Grant & Hayek Fund Awards (x2), Institute for Humane Studies at George Mason University

2017
Certificate in University and College Teaching, Cornell University
Certificate in Academic Research Mentoring, Cornell University

2016 – 2017
Graduate Research and Teaching Fellowship ($1,000), Center for Teaching Excellence, Cornell University

2016
Human Ecology Alumni Association Student Research Grant, Cornell University

2014
Economics Department Masters’ Program Conference Travel Grant, Duke University

2013 – 2014
Department of Economics Master’s Scholarship (Tuition Waiver), Duke University

2012
Outstanding Graduate Awards by Beijing Municipal Commission of Education

2011
Outstanding Student Awards by Beijing Municipal Commission of Education
“Challenge Cup” National Academic Science & Technology Competition, 2nd prize in Beijing
Principal Investigator, China Ping An National Academic Dissertation Contest (¥5,000), 2nd Prize National

2010
China National Undergraduate Mathematical Contest in Modeling, 2nd prize National
China Banking Association Micro Entrepreneurship Investigator Grant
Principal Investigator, China Ping An National Academic Dissertation Contest (¥10,000), 1st Prize National

2009
National Insurance Education Hope Scholarship (¥8,000), Insurance Society of China

2010 – 2012
Top 10 Individuals/Teams in Research, Central University of Finance and Economics, Beijing

2009 – 2012
Principal Investigator, National Undergraduate Research Innovation Grant (¥10,000), Ministry of Education of the People’s Republic of China
Summer Investigator Grants (Univ.-wide bid), Conference Grants (School of Insurance), Central University of Finance and Economics, Beijing

2008 – 2012
Excellent Undergraduate Scholarship, Central University of Finance and Economics, Beijing

Publications

Articles in Refereed Journals

Chatterjee, Chirantan; Chugunova, Marina; Ghosh, Mainak; Singhal, Abhay; Wang, Lucy Xiaolu (2023). Human Mediation Leads to Higher Compliance in Digital Mental Health: Field Evidence from India, Frontiers in Behavioral Economics, 2. DOI

    Kreyer, Ann-Christin; Wang, Lucy Xiaolu (2022). Collaborating Neuroscience Online: The Case of the Human Brain Project Forum, PLoS One, 17 (12). DOI

    • This paper analyzes user interactions on the public-access online forum of the Human Brain Project (HBP), a major European Union-funded neuroscience research initiative, to understand the utility of the Forum for collaborative problem solving. We construct novel data using discussion forum posts and detailed user profiles on the HBP Forum. We find that HBP Forum utilization is comparable to that of a leading general-interest coding platform, and that online usage metrics quickly recovered after an initial Covid-19-related dip. Regression results show that user interactions on the Forum are more active for questions on programming and in HBP core areas. Further, Cox proportional hazard analyses show that such problems are solved faster. Forum posts with users from different countries tend to be discussed more actively but solved slower. Higher shares of administrator support tend to solve problems faster. There are no clear patterns regarding gender and seniority. Our results suggest that building novel collaborative forums can support researchers working on complex topics in challenging times.
    • Also published as: Max Planck Institute for Innovation & Competition Research Paper No. 22-10

    Wang, Lucy Xiaolu (2021). Medicines Patent Pool and HIV Drug Cocktail Diffusion and Innovation, Academy of Management Proceedings, 2021 (1). DOI

    • Designed to reward innovation, patent protection often leads to high drug prices that make life-saving medicines unaffordable for patients. This tension further increases patent infringement and invalidation to reduce prices, particularly in developing countries. The situation is serious for treatments that require multiple drugs owned by different firms with numerous patents, notably for HIV. I study the impact of the first joint licensing platform for drug bundling, the Medicines Patent Pool (MPP), on global drug diffusion and innovation. The pool allows generic firms worldwide to license drug bundles cheaply and conveniently for sales in a set of developing countries. I construct a novel dataset from licensing contracts, public procurement, clinical trials, and drug approvals. Using difference-in-differences methods, I find robust evidence that the pool leads to a substantial increase in the generic supply of drugs purchased. In addition, branded-drug makers and other entities, such as public institutions, respond to the pool by increasing the number of new clinical trials. The R&D input increase is accompanied by increases in generic drug product approvals. Finally, I estimate a simple structural model to quantify welfare gains and simulate counterfactuals. The total benefit to consumers and firms far exceeds the associated costs. The MPP has become the key implementing partner for the WHO's COVID-19 Technology Access Pool and deserves more future research.

    Wang, Lucy Xiaolu (2021). The Complementarity of Drug Monitoring Programs and Health It for Reducing Opioid-Related Mortality and Morbidity, Health Economics, 30 (9), 2026-2046. DOI

    • In response to the opioid crisis, each US state has implemented a prescription drug monitoring program (PDMP) to collect data on controlled substances prescribed and dispensed in the state. I study whether health information technology (HIT) complements patient prescription data in PDMPs to reduce opioid-related mortality and morbidity. A novel dataset is constructed that records state policies that integrate PDMP with HIT and facilitate interstate data sharing. Using difference-in-differences models, I find that PDMP-HIT integration policies reduce opioid-related inpatient morbidity. The reductions are substantial in states that established integration without ever mandating the use of a PDMP. A mechanism test suggests that PDMP integration works mainly through the hospital system while a mandate affects legal opioids prescription. The impacts from integration are strongest for the vulnerable groups—middle-aged, low-to middle-income patients, and those with public insurance. There is suggestive evidence that interstate data sharing further complements integration despite not having a significant impact independently. The results are robust to a set of tests using alternative specifications and measures. The total benefits from integration far exceed the associated costs.

    Epstein, Jordan; Nicholson, Sean; Wang, Lucy Xiaolu; Hempstead, Katherine; Asin, Sam (2020). The Secret Menu in Health Care: A Cash Market for Imaging in California, INQUIRY: The Journal of Health Care Organization, Provision, and Financing 2020. DOI

    • In addition to the prices they negotiate with private health insurers, most providers also have a cash price schedule for patients who have the wherewithal to ask and are willing to pay in full when they receive a service. This is the first study that estimates the potential cost saving of allowing privately-insured consumers to observe both in-network negotiated prices and cash prices, which is of particular interest given the growing importance of high-deductible health plans and a recent executive order mandating greater price transparency. Using data from five private health insurers and 142 imaging facilities in the San Francisco Bay Area, we estimate that patients could save between 10% and 22% of their insurer’s in-network price by paying cash. Potential savings are much larger (between 45% and 64% of their insurer’s in-network price) if consumers observe both cash and in-network prices and select the facility in the region offering the lowest price for a particular service.
    • Also published as: Max Planck Institute for Innovation & Competition Research Paper No. 21-05

    Contributions to Collected Editions

    Cassidy, Alecia W.; Tower, Edward; Wang, Lucy Xiaolu (2015). Manufacturing Fetishism: The Neo-Mercantilist Preoccupation with Protecting Manufacturing, in: Amitrajeet Batabyal, Peter Nijkamp (eds.), The Region and the Trade: New Analytical Directions, 137-175. New Jersey: World Scientific. DOI

    Discussion Papers

    Byrski, Dennis; Wang, Lucy Xiaolu (2024). Marketing Authorization and Strategic Patenting: Evidence from Pharmaceuticals. DOI

    • Patents are designed to incentivize innovation, but pharmaceutical firms often extend market exclusivity with secondary patents on marginally beneficial improvements. Such behaviors evoke discussions about raising patentability standards. This study examines whether pharmaceutical firms move away from filing strategic patents once the focal drug gains marketing authorization and the disclosed trial-related information becomes novelty-threatening prior art. We construct novel patent-drug dyadic data and leverage unique European drug patent and marketing contexts. Using an event study methodology, we exploit plausibly exogenous variation in the length of time from patent filing to drug approval. First, we illustrate that drugs with early and late marketing authorization share similar ex ante patent and drug characteristics. Second, we support the hypothesis that strategic patenting behavior decreases substantially after marketing authorization. In contrast, meaningful follow-on innovations remain unaffected. Third, we show that these effects are likely driven by obstacles in the enforceability of marginal patents filed after approval. We analyze heterogeneity across firm type, patent type, disease type, and enforceability. Our results suggest that post-marketing increases in patentability standards are welfare-enhancing with examiner scrutiny and firm self-adjustment. We highlight the importance of better data provision to patent examiners to increase the quality of follow-up inventions.

    Wang, Lucy Xiaolu (2023). A Cost-Benefit Analysis of the Medicines Patent Pool, Max Planck Institute for Innovation & Competition Research Paper, No. 23-18. DOI

    • Understanding the cost and benefit of global public health institutions is important but challenging. This study provides a cost-benefit analysis of the first public health-oriented patent pooling and licensing institution, the Medicines Patent Pool (MPP), which is devoted to improving generic drug licensing and supply in low- and middle-income countries. A simple structural model of demand and supply is estimated on a dataset that covers 103 LMIC and 29 HIV drugs with data on sales, MPP licenses, patents, country-year level diseases and demographics, and institutional factors during 2007-2017. Counterfactuals are simulated in the absence of the MPP or with further expansions. The estimated benefits to consumers and firms far exceed the operating costs.

    Kreyer, Ann-Christin; Wang, Lucy Xiaolu (2022). Collaborating Neuroscience Online: The Case of the Human Brain Project Forum, Max Planck Institute for Innovation & Competition Research Paper, No. 22-10. DOI

    • This paper analyzes user interactions on the public-access online forum of the Human Brain Project (HBP), a major European Union-funded neuroscience research initiative, to understand the utility of the Forum for collaborative problem solving. We construct novel data using discussion forum posts and detailed user profiles on the HBP Forum. We find that HBP Forum utilization is comparable to that of a leading general-interest coding platform, and that online usage metrics quickly recovered after an initial Covid-19-related dip. Regression results show that user interactions on the Forum are more active for questions on programming and in HBP core areas. Further, Cox proportional hazard analyses show that such problems are solved faster. Forum posts with users from different countries tend to be discussed more actively but solved slower. Higher shares of administrator support tend to solve problems faster. There are no clear patterns regarding gender and seniority. Our results suggest that building novel collaborative forums can support researchers working on complex topics in challenging times.
    • Also published in: PLoS ONE 17(12): e0278402

    Wang, Lucy Xiaolu; Wilson, Nicholas (2022). U.S. State Approaches to Cannabis Licensing, Max Planck Institute for Innovation & Competition Research Paper, No. 22-09.

    • U.S. states have taken varied approaches to licensing cannabis businesses under federal prohibition, but up to now there is limited research on cross-state licensing approaches. This paper provides a systematic analysis of the current licensing strategies taken by all states that have passed medical cannabis laws (MCLs)/recreational cannabis laws (RCLs). We construct comprehensive data on cannabis business licenses offered in each state, as well as metrics for license categories, cost, and issuance volume. We then analyze patterns between these metrics, also considering how long ago states implemented MCLs/RCLs, qualitative licensing aspects, state ideology and voting preference, and state cannabis taxation data. We observe that states tend to license medical cannabis more restrictively than adult-use cannabis: i.e., by offering licenses in fewer categories, at higher cost, in lower issuance volume, and more often mandating vertical integration. Additionally, states that implemented MCLs/RCLs earlier tend to offer licenses in more categories, at lower cost, and in greater issuance volumes. Further, though states that implemented MCLs recently lean conservative and Republican, we do not observe clear relationships between ideology or voting preference and licensing policy. In our supporting results, we observe that a greater share of states with complex licensing structures impose non-retail price cannabis taxes than states overall, and we discuss how states have changed their licensing policies over time.
    • Available at SSRN

    Wang, Lucy Xiaolu (2021). The Complementarity of Drug Monitoring Programs and Health IT for Reducing Opioid-Related Mortality and Morbidity, Max Planck Institute for Innovation & Competition Research Paper, No. 21-14. DOI

    • In response to the opioid crisis, each U.S. state has implemented a prescription drug monitoring program (PDMP) to collect data on controlled substances prescribed and dispensed in the state. I study whether health information technology (HIT) complements the availability of patient data in PDMPs to reduce opioid-related mortality and morbidity. I construct a novel dataset that records state policies that integrate PDMP with HIT and facilitate interstate data sharing. Using difference-in-differences models, I find that PDMP-HIT integration policies reduce opioid-related mortality and morbidity. The reductions in inpatient morbidity are substantial in states that established integration without ever mandating the use of a PDMP. The impacts are strongest for the most vulnerable groups – middle-age, low- to middle-income patients, and those with public insurance. I find suggestive evidence that interstate data sharing further complements integration despite not having a significant impact independently. The total benefits from integration far exceed the associated costs.

    Epstein, Jordan; Nicholson, Sean; Wang, Lucy Xiaolu; Hempstead, Katherine; Asin, Sam (2021). The Secret Menu in Health Care: A Market for Imaging in California, Max Planck Institute for Innovation & Competition Research Paper, No. 21-05.

    • In addition to the prices they negotiate with private health insurers, most providers also have a cash price schedule for patients who have the wherewithal to ask and are willing to pay in full when they receive a service. This is the first study that estimates the potential cost saving of allowing privately-insured consumers to observe both in-network negotiated prices and cash prices, which is of particular interest given the growing importance of high-deductible health plans and a recent executive order mandating greater price transparency. Using data from five private health insurers and 142 imaging facilities in the San Francisco Bay Area, we estimate that patients could save between 10 percent and 22 percent of their insurer’s in-network price by paying cash. Potential savings are much larger (between 45 percent and 64 percent of their insurer’s in-network price) if consumers observe both cash and in-network prices and select the facility in the region offering the lowest price for a particular service.
    • Available at SSRN
    • Also published in: INQUIRY - The Journal of Health Care Organization, Provision, and Financing, Volume 57, First published online December 25, 2020

    Wang, Lucy Xiaolu (2020). Global Drug Diffusion and Innovation with a Patent Pool: The Case of HIV Drug Cocktails. DOI

    • Designed to reward innovation, patent protection often leads to high drug prices that make life-saving medicines unaffordable for patients. This tension further induces increasing patent infringement and invalidation to reduce prices, particularly in developing countries. The situation is serious for treatments that require multiple drugs owned by different firms with numerous patents, notably for HIV. I study the impact of the first joint licensing platform for drug bundling, the Medicines Patent Pool, on global drug diffusion and innovation. The pool allows generic firms worldwide to sublicense drug bundles cheaply and conveniently for sales in a set of developing countries. I construct a novel dataset from licensing contracts, public procurement, clinical trials, and drug approvals. Using difference-in-differences methods, I find robust evidence that the pool leads to a substantial increase in generic supply of drugs purchased. In addition, the branded-drug makers and other entities, such as public institutions, respond to the pool by increasing the number of new clinical trials. The R&D input increase is accompanied by increases in generic drug product approvals. Finally, I estimate a structural model to quantify welfare gains and simulate counterfactuals. The total benefit far to consumers and firms exceeds the associated costs.

    Wang, Lucy Xiaolu (2020). Patent Classification Systems and Technological Categorization: An Overview and Data Update. DOI

    • Patent classification systems and upper-level grouping datasets have been widely used for research and entrepreneurial purposes but are insufficiently documented. This article provides an overview of the major patent classification systems and the basic ideas behind categorization of the data on patent classes. I highlight recent institutional changes that disproportionately affect patents in specific categories and alternative categorizations used in the patent examination process. Finally, I update the National Bureau of Economic Research patent technological categorization based on the latest U.S. patent classification. The resulting datasets can be used in numerous follow-up analyses using patent data to investigate innovation and entrepreneurship.

    Epstein, Jordan; Nicholson, Sean; Wang, Lucy Xiaolu; Hempstead, Katherine; Asin, Sam (2020). The Secret Menu in Health Care: A Cash Market for Imaging in California, Working Paper.

    • Funded by a Robert Wood Johnson Foundation Grant awarded in 2016 (Principal Investigator: J. Epstein)
    • In addition to the prices they negotiate with private health insurers, most providers also have a cash price schedule for patients who have the wherewithal to ask and are willing to pay in full when they receive a service. This is the first study to our knowledge that estimates the potential benefits of allowing privately-insured consumers to observe both in-network negotiated prices and cash prices, which is of particular interest given the growing importance of high-deductible health plans. Using data from five private health insurers and 142 imaging facilities in the San Francisco Bay Area, we estimate that patients could save between 10 percent and 22 percent of their insurer’s in-network price by paying cash. Potential savings are much larger (between 45 percent and 64 percent of their insurer’s in-network price) if consumers observe both cash and in-network prices and select the facility in the region offering the lowest price for a particular service.

    Cassidy, Alecia W.; Tower, Edward; Wang, Lucy Xiaolu (2016). Manufacturing Fetishism: The Neo-Mercantilist Preoccupation with Protecting Manufacturing, Economic Research Initiatives at Duke (ERID) Working Paper, No. 227.

    • Two common views are that a country cannot develop without a strong manufacturing base and that trade restrictions are essential to facilitate the development of that strong manufacturing base and thus spur economic growth. We ask:
      Does a strong manufacturing share of GDP facilitate economic growth?
      Do trade restrictions ensure the development of a strong manufacturing base?
      How can governance affect manufacturing share?
      And are the relationships we find robust across regions?
      We find the manufacturing share is not significantly correlated with a higher standard of living. Nor is it related significantly and consistently to economic growth. We also find that trade restrictions both at home and abroad shrink the manufacturing base and smother economic growth. A better way than protectionism and subsidies specific to industry to enhance economic growth is to improve governance effectiveness and the quality of regulation.
    • Available at SSRN
    • Also published in: The Region and Trade, pp. 137-175 (2015)

    Presentations

    12/09/2021
    Procurement Institutions and Essential Drug Supply in Low and Middle-Income Countries
    iHEA Health System Efficiency SIG webinar
    Location: online


    11/24/2021
    Global Drug Diffusion and Innovation with the Medicines Patent Pool
    European Health Economics Association (EuHEA) seminar
    Location: online


    11/06/2021
    Procurement Institutions and Essential Drug Supply in Low and Middle-Income Countries
    North East Universities Development Consortium (NEUDC), Boston University
    Location: online


    10/07/2021
    Global Drug Diffusion and Innovation with the Medicines Patent Pool
    Management, Strategy and Innovation seminar, KU Leuven, Belgien
    Location: online


    08/03/2021
    Medicines Patent Pool and HIV Drug Cocktail Diffusion and Innovation
    Annual Meeting of Academy of Management
    Location: online


    07/20/2021
    Is Grass Greener in the Gray Zone? Innovation in the Cannabis Market
    Behavioral & Empirical Work in Progress (BEWIP) seminar, TU München (School of Management)
    Location: online


    07/13/2021
    Global Drug Diffusion and Innovation with the Medicines Patent Pool
    International Health Economics Association (iHEA) World Congress
    Location: online


    07/13/2021
    Procurement Institutions and Essential Drug Supply in Low and Middle-Income Countries
    International Health Economics Association (iHEA) World Congress
    Location: online


    07/09/2021
    Procurement Institutions and Essential Drug Supply in Low and Middle-Income Countries
    Intellectual Property & Innovation PhD seminar, Université de Lausanne
    Location: online


    06/24/2021
    Procurement Institutions and Essential Drug Supply in Low and Middle-Income Countries
    TIME Colloquium
    Location: online


    06/23/2021
    Is Grass Greener in the Gray Zone? Innovation in the Cannabis Market
    10th Conference of American Society of Health Economists
    Location: online


    06/23/2021
    Procurement Institutions and Essential Drug Supply in Low and Middle-Income Countries
    10th Conference of American Society of Health Economists
    Location: online


    06/21/2021
    Global Drug Diffusion and Innovation with the Medicines Patent Pool
    10th Conference of American Society of Health Economists
    Location: online


    06/17/2021
    Global Drug Diffusion and Innovation with the Medicines Patent Pool
    Spring Meeting of Young Economists, University of Bologna
    Location: online


    06/14/2021
    Is Grass Greener in the Gray Zone? Innovation in the Cannabis Market
    LMU Innovation Workshop
    Location: online


    06/04/2021
    Procurement Institutions and Essential Drug Supply in Low and Middle-Income Countries
    Industry Studies Association Annual Conference
    Location: online


    06/04/2021
    Global Drug Diffusion and Innovation with the Medicines Patent Pool
    Industry Studies Association Annual Conference
    Location: online


    05/13/2021
    Global Drug Diffusion and Innovation with the Medicines Patent Pool
    Shanghai International College of Intellectual Property
    Location: online


    05/01/2021
    Global Drug Diffusion and Innovation with the Medicines Patent Pool
    19th International Industrial Organization Conference
    Location: online


    03/12/2021
    Global Drug Diffusion and Innovation with the Medicines Patent Pool
    Mannheim Centre for Competition and Innovation (MaCCI) Annual Conference (presenter & discussant)
    Location: online


    03/12/2021
    Innovation Cost and the Nature and Direction of Learning: Manufacturing Change and Automation
    Mannheim Centre for Competition and Innovation (MaCCI) Annual Conference (presenter & discussant)
    Location: online


    02/17/2021
    Global Drug Diffusion and Innovation with the Medicines Patent Pool
    Columbia University (Mailman School of Public Health)
    Location: online


    12/07/20
    Global Drug Diffusion and Innovation With the Medicines Patent Pool
    New York University, Stern School of Business, MBA guest speaker
    Location: online


    12/04/20
    Global Drug Diffusion and Innovation With the Medicines Patent Pool
    NBER Entrepreneurship Working Group Meeting+
    Location: online


    09/02/20
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    U.S. Food and Drug Administration Research Brownbag
    Location: online (Washington D.C., United States)


    08/13/20
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Chinese Economists Society North America Meeting
    Location: online (Boston, United States)


    06/05/20
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Industry Studies Association Annual Conference
    Location: online (Boston, United States)


    02/14/20
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    University of Sydney Seminar
    Location: Sydney, Australia


    02/10/20
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    National University of Singapore (Business School) Seminar
    Location: virtual


    02/06/20
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Melbourne Institute: Applied Economic and Social Research Seminar
    Location: Melbourne, Australia


    01/31/20
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    RAND Corporation Seminar
    Location: Washington, DC, United States


    01/29/20
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    University of Illinois at Chicago, Department of Economics Seminar
    Location: Chicago, United States


    01/22/20
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    University of Massachusetts Amherst (Resource Economics) Seminar
    Location: Amherst, United States


    01/15/20
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Max Planck Institute for Innovation and Competition, Innovation & Entrepreneurship Seminar
    Location: Munich, Germany


    01/03/20
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    American Economic Association Annual Meeting
    Location: San Diego, United States


    12/17/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Econometric Society European Winter Meeting
    Location: Rotterdam, Netherlands


    12/09/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    UC Berkeley (Haas School of Business) Seminar
    Location: Berkeley, United States


    12/04/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Charles River Associates Seminar
    Location: Boston, United States


    12/03/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    NBER Productivity Seminar
    Location: Cambridge, United States


    11/25/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Cornerstone Research Seminar
    Location: New York City, United States


    11/09/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Association for Public Policy Analysis & Management Fall Research Conference
    Location: Denver, United States


    10/26/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Economics Graduate Student Conference, Washington Univ. in St. Louis
    Location: St. Louis, United States


    10/20/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Institute for Operations Research and the Management Sciences (INFORMS) Annual Meeting
    Location: Seattle, United States


    10/11/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Wharton Innovation Doctoral Symposium
    Location: Philadelphia, United States


    10/05/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    North East Universities Development Consortium, Northwestern University
    Location: Evanston, United States


    09/13/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    European Policy for Intellectual Property, ETH Zürich
    Location: Zurich, Switzerland


    08/12/19
    The Complementarity of Health Information and Health IT for Reducing Opioid-Related Mortality and Morbidity
    Annual Meeting of the Academy of Management
    Location: Boston, United States


    08/09/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    19th Annual Intellectual Property Scholars Conference, DePaul University (Law School)
    Location: Chicago, United States


    07/15/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    International Health Economics Association World Congress
    Location: Basel, Switzerland


    07/08/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    Medicines Patent Pool seminar
    Location: Geneva, Switzerland


    06/25/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    8th Conference of the American Society of Health Economists (Poster)
    Location: Washington, D.C., United States


    06/09/19
    Global Drug Diffusion and Innovation With a Patent Pool: The Case of HIV Drug Cocktails
    26th Consortium for Competitiveness and Cooperation (CCC) Conference
    Location: Durham/Chapel Hill, United States


    05/31/19
    The Complementarity of Health Information and Health IT for Reducing Opioid-Related Mortality and Morbidity
    Global Drug Diffusion and Innovation with a Patent Pool: The Case of HIV Drug Cocktails

    Industry Studies Association Conference (x2, healthcare; innovation)
    Location: Nashville, United States


    01/04 - 01/06/19
    The Growing Shadow of Patent Litigation: Patentability Uncertainty and Strategic Reactions
    American Economic Association Annual Meeting (Poster)
    Location: Atlanta, United States